956697-53-3 Usage
Description
NVP-LDE225, also known as a potent, selective, and orally bioavailable Smoothened (SMO) antagonist, is a member of the class of biphenyls. It is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. It inhibits the hedgehog (Hh) signaling pathway via antagonism of the Smoothened receptor (SMO) and is used as an antineoplastic agent.
Uses
Used in Pharmaceutical Industry:
NVP-LDE225 is used as an antineoplastic agent for the treatment of locally advanced basal cell carcinoma. It functions as a potent Hedgehog inhibitor, targeting the hedgehog signaling pathway and reducing the growth and progression of cancer cells.
Used in Cancer Research:
NVP-LDE225 is used as a research tool in cancer research to study the role of the hedgehog signaling pathway in various types of cancer. It helps researchers understand the molecular mechanisms underlying the development and progression of cancer and identify potential therapeutic targets for cancer treatment.
Biological Activity
lde225 is a potent and selective inhibitor of smoothened with ic50 values of 1.3nm in mouse and 2.5nm in human, respectively [1].lde225 is screened out from a high-throughput cell-based screen of in-house diversity combinatorial libraries and is developed to be an antagonist of smo. smo is an activator of the hedgehog(hh) signaling pathway and aberrant activation links to tumorigenesis in several cancers. the antitumor efficacy of lde225 has been evaluated in vivo. in the subcutaneous ptch+/-p53-/- medulloblastoma allograft mouse model, lde225 can significantly inhibit tumor growth at a dose of 5mg/kg/day. and in an orthotopic ptch+/-p53-/- medulloblastoma allograft model, lde225 is suggested to penetrate the blood-brain barrier in tumor-bearing animals and cause the tumor growth inhibition after 4 days of treatment. additionally, the preclinical safety assays show that lde225 has no genotoxicity and has good selectivity [1].
references
[1] shifeng pan, xu wu, jiqing jiang, et al. discovery of nvp-lde225, a potent and selective smoothened antagonist. acs med. chem. lett. 2010, 1: 130–134.
Check Digit Verification of cas no
The CAS Registry Mumber 956697-53-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,6,6,9 and 7 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 956697-53:
(8*9)+(7*5)+(6*6)+(5*6)+(4*9)+(3*7)+(2*5)+(1*3)=243
243 % 10 = 3
So 956697-53-3 is a valid CAS Registry Number.
956697-53-3Relevant articles and documents
Large-steric-hindrance N-heterocyclic carbene palladium complex, preparation method and application thereof, and synthesis method of sonidegib based on large-steric-hindrance N-heterocyclic carbene palladium complex
-
, (2021/01/24)
The invention belongs to the technical field of organic synthesis and chemical catalysis, and discloses a large-steric-hindrance N-heterocyclic carbene palladium complex, a preparation method thereof,an application of the complex in efficient catalysis of a C-N coupling reaction under a room-temperature air condition, and a synthesis method of sonidegib based on the complex. According to the large-steric-hindrance N-heterocyclic carbene palladium complex, diphenyl imidazole serves as a main ligand framework, functionalized allyl serves as an auxiliary ligand, the functionalized allyl is introduced beside a metal center of a catalyst to serve as an auxiliary ligand, the catalytic activity and stability are remarkably improved, the large-steric-hindrance N-heterocyclic carbene palladium complex can be applied to efficient catalysis of a CN coupling reaction, particularly, the CN coupling reaction can be efficiently catalyzed under the room temperature condition, and the yield can reachup to 99%. The invention also provides a method for synthesizing sonidegib by taking aryl/aliphatic amine and aryl chloride as reactants and a three-step method at room temperature under the catalysisof a palladium catalytic system, the synthetic method has few steps, and the total yield can reach 74.5%.
Preparation methods of Sonidegib intermediate and Sonidegib
-
, (2019/02/13)
The invention provides preparation methods of a Sonidegib intermediate and Sonidegib. According to the preparation methods, 2-amino-5-nitropyridine (II) and R-propylene oxide (or S-propylene oxide) are subjected to an epoxy ring-opening substitution react
The topical pharmaceutical compositions comprising active agent
-
, (2016/10/09)
The present invention relates to pharmaceutical compositions of 2-Methyl-4′-trifluoromethoxy-biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide, to the use of such compositions in therapeutic applications and to methods for manufacturing such compositions.
